文献速递白血病

维奈克拉联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
PubMed 文献 · Blood · 2018-10-25

这项多中心1b期剂量递增和扩展研究纳入145例≥65岁、不适合强化化疗的初治AML患者,评估维奈克拉联合地西他滨或阿扎胞苷的安全性和疗效。所有剂量组完全缓解+完全缓解伴计数不完全恢复(CR+CRi)率为67%,维奈克拉400 mg+去甲基化药物(HMA)队列为73%,中位总生存17.5个月,未观察到肿瘤溶解综合征。

要点

  • 所有剂量组CR+CRi率为67%,维奈克拉400 mg+HMA队列为73%。
  • 高危细胞遗传学患者和≥75岁患者CR+CRi率分别为60%和65%。
  • 所有患者中位CR+CRi持续时间11.3个月,中位总生存17.5个月。

核心结论

  • 维奈克拉联合地西他滨或阿扎胞苷在老年AML患者中有效且耐受性良好。

研究设计与样本

  • 多中心1b期剂量递增和扩展研究,纳入145例≥65岁、不适合强化化疗的初治AML患者。
  • 剂量递增阶段维奈克拉口服400、800或1200 mg每日联合地西他滨(20 mg/m2,第1-5天,静脉注射)或阿扎胞苷(75 mg/m2,第1-7天,静脉注射或皮下注射)。
  • 扩展阶段给予维奈克拉400或800 mg联合任一去甲基化药物(HMA)。
  • 中位年龄74岁,49%患者为高危细胞遗传学。

主要发现

  • 所有剂量组CR+CRi率为67%,维奈克拉400 mg+HMA队列为73%。
  • 高危细胞遗传学患者CR+CRi率为60%,≥75岁患者为65%。
  • 所有患者中位CR+CRi持续时间为11.3个月,中位总生存为17.5个月;维奈克拉400 mg队列中位总生存未达到。
  • 中位研究时间为8.9个月,未观察到肿瘤溶解综合征。
  • 常见不良事件(>30%)包括恶心、腹泻、便秘、发热性中性粒细胞减少、疲乏、低钾血症、食欲下降和白细胞计数降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance. We report safety and efficacy of venetoclax with decitabine or azacitidine from a large, multicenter, phase 1b dose-escalation and expansion study. Patients (N = 145) were at least 65 years old with treatment-naive AML and were ineligible for intensive chemotherapy. During dose escalation, oral venetoclax was administered at 400, 800, or 1200 mg daily in combination with either decitabine (20 mg/m2, days 1-5, intravenously [IV]) or azacitidine (75 mg/m2, days 1-7, IV or subcutaneously). In the expansion, 400 or 800 mg venetoclax with either hypomethylating agent (HMA) was given. Median age was 74 years, with poor-risk cytogenetics in 49% of patients. Common adverse events (>30%) included nausea, diarrhea, constipation, febrile neutropenia, fatigue, hypokalemia, decreased appetite, and decreased white blood cell count. No tumor lysis syndrome was observed. With a median time on study of 8.9 months, 67% of patients (all doses) achieved complete remission (CR) + CR with incomplete count recovery (CRi), with a CR + CRi rate of 73% in the venetoclax 400 mg + HMA cohort. Patients with poor-risk cytogenetics and those at least 75 years old had CR + CRi rates of 60% and 65%, respectively. The median duration of CR + CRi (all patients) was 11.3 months, and median overall survival (mOS) was 17.5 months; mOS has not been reached for the 400-mg venetoclax cohort. The novel combination of venetoclax with decitabine or azacitidine was effective and well tolerated in elderly patients with AML (This trial was registered at www.clinicaltrials.gov as #NCT02203773).

来源:Blood,查看原文。版权归原作者所有。

引用

  1. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2018. PMID: 30361262. doi:10.1182/blood-2018-08-868752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。